Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines

Tumor Biology

Volumn 36, Issue 2, 2015, Pages 779-786

  Varol, Umut ^a   Degirmenci, Mustafa ^b   Karaca, Burcak ^c   Atmaca, Harika ^d   Kisim, Asli ^d   Uzunoglu, Selim ^d   Sezgin, Canfeza ^c   Sanli, Ulus Ali ^c   Uslu, Ruchan ^c  

^a IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

^b Izmir Tepecik Training and Research Hospital Eye Clinic   (Turkey)

^c EGE UNIVERSITY   (Turkey)

^d CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Cytotoxicity; Docetaxel resistance; Prostate cancer; Zoledronic acid

Indexed keywords

CASPASE 3; CASPASE 7; DOCETAXEL; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; TAXOID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; NEOPLASMS, HORMONE-DEPENDENT; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHOSPHONATES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; IMIDAZOLES; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84925499017     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2682-6     Document Type: Article

References (29)

1. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory cancer: a Hoosier Oncology Group and Fox Chase Network Phase III Trial. J Clin Oncol. 1999;17:3160.
2. Semenas J, Allegrucci C, Boorjian SA, Mongan NP, Persson JL. Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets. 2012;13:1308–23.
3. Lin JC, Chang SY, Hsieh DS, Lee CF, Yu DS. The association of Id-1, MIF and GSTpi with acquired drug resistance in hormone independent prostate cancer cells. Oncol Rep. 2005;13:983–8.
4. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8:12–23.
5. Fabbri F, Brigliadori G, Carloni S, Ulivi P, Tesei A, Silvestrini R, et al. Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression. Prostate. 2010;70:219–27.
6. Serafin AM, Akudugu JM, Bohm L. Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status. Urol Res. 2002;30:289–94.
7. Kubo H, Sumizawa T, Koga K, Nishiyama K, Takebayashi Y, Chuman Y, et al. Expression of the multidrug resistance-associated protein (MRP) gene in urothelial carcinomas. Int J Cancer. 1996;69:488.
8. Lin JC, Chang SY, Hsieh DS, Lee CF, Yu DS. Modulation of mitogen-activated protein kinase cascades by differentiation-1 protein: acquired drug resistance of hormone independent prostate cancer cells. J Urol. 2005;174:2022–6.
9. Beer TM, El Geneidi M, Eilers KM. Docetaxel (taxotere) in the treatment of prostate cancer. Expert Rev Anticancer Ther. 2003;3:261–8.
10. Hong WK. The current status of docetaxel in solid tumors. An M.D. Anderson Cancer Center review. Oncology (Huntingt). 2002;16:9–15.
11. Li Y, Li X, Hussain M, Sarkar FH. Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray. Neoplasia. 2004;6:158–67.
12. Petrylak DP, Tangen CM, Hussain MH. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.
13. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 2003;9:295–306.
14. Dumon JC, Journé F, Kheddoumi N, Lagneaux L, Body JJ. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol. 2004;45:521–8.
15. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001;61:2602–8.
16. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol. 2003;170:246–52.
17. Skjoth IH, Issinger OG. Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis. Int J Oncol. 2006;28:217.
18. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621–81.
19. Hara T, Ushio K, Nishiwaki M, Kouno J, Araki H, Hikichi Y, et al. A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line. Cell Biol Int. 2010;34:177–84.
20. Lo Nigro C, Maffi M, Fischel JL, Formento P, Milano G, Merlano M. The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. BJU Int. 2008;102:622–7.
21. Wiltshire C, Singh BL, Stockley J, Fleming J, Doyle B, Barnetson R, et al. Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition. Mol Cancer Ther. 2010;9:1730–9.
22. O’Connell K, Prencipe M, O’Neill A, Corcoran C, Rani S, Henry M, et al. The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines. Proteomics. 2012;12:2115–26.
23. Marín-Aguilera M, Codony-Servat J, Kalko SG, Fernández PL, Bermudo R, Buxo E, et al. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther. 2012;11:329–39.
24. Fabbri F, Brigliadori G, Carloni S, Ulivi P, Vannini I, Tesei A, et al. Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med. 2008;6:43.
25. Morgan C, Lewis PD, Jones RM, Bertelli G, Thomas GA, Leonard RC. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncol. 2007;46:669–77.
26. Saad F. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer. 2002;1:145–52.
27. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Zoledronic acid prostate cancer study group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879–82.
28. Ullén A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kälkner KM, Lennernäs B, et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol. 2005;44:644–50.
29. Karabulut B, Erten C, Gul MK, Cengiz E, Karaca B, Kucukzeybek Y, et al. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int. 2009;33:239–46.